Business
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the presentations are outlined below. Poster Presentation Title: Early, Transient Shift in Hematologic Parameters Observed with Ublituximab in the ULTIMATE I and II Phase 3 Studies Presentation Date/Time: Thursday, February 23, 7:00 - 7:30 PM PSTSession: Poster Session 1Abstract Number/Poster Number: 406/P071Lead Author: Peiqing Qian, MD, Swedish Neuroscience Institute, Seattle, WA Poster Presentation Title: Onset and Maintenance of No Evidence of Disease Activity with Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants with Relapsing Multiple Sclerosis Presentation Date/Time: Thursday, February 23, 6:30 - 7:00 PM PSTSession: Poster Session 1Abstract Number/Poster Number: 409/P082Lead Author: Enrique Alvarez, MD, University of Colorado, Aurora, CO A copy of the above abstracts can be found on the ACTRIMS meeting website. Following the presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm. ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous y...